These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 11846231)

  • 1. Dendritic cell-based vaccination strategies: induction of protective immunity against leishmaniasis.
    Moll H; Berberich C
    Immunobiology; 2001 Dec; 204(5):659-66. PubMed ID: 11846231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vaccination with plasmacytoid dendritic cells induces protection against infection with Leishmania major in mice.
    Remer KA; Apetrei C; Schwarz T; Linden C; Moll H
    Eur J Immunol; 2007 Sep; 37(9):2463-73. PubMed ID: 17705130
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fragments of antigen-loaded dendritic cells (DC) and DC-derived exosomes induce protective immunity against Leishmania major.
    Schnitzer JK; Berzel S; Fajardo-Moser M; Remer KA; Moll H
    Vaccine; 2010 Aug; 28(36):5785-93. PubMed ID: 20615489
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Vaccine-induced protection against Leishmania amazonensis is obtained in the absence of IL-12/23p40.
    Hernández MX; Barçante TA; Vilela L; Tafuri WL; Afonso LC; Vieira LQ
    Immunol Lett; 2006 May; 105(1):38-47. PubMed ID: 16466810
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis.
    Iborra S; Soto M; Carrión J; Alonso C; Requena JM
    Vaccine; 2004 Sep; 22(29-30):3865-76. PubMed ID: 15364433
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dendritic cell (DC)-based protection against an intracellular pathogen is dependent upon DC-derived IL-12 and can be induced by molecularly defined antigens.
    Berberich C; Ramírez-Pineda JR; Hambrecht C; Alber G; Skeiky YA; Moll H
    J Immunol; 2003 Mar; 170(6):3171-9. PubMed ID: 12626575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of potential protection induced by three vaccination strategies (DNA/DNA, Protein/Protein and DNA/Protein) against Leishmania major infection using Signal Peptidase type I in BALB/c mice.
    Rafati S; Ghaemimanesh F; Zahedifard F
    Vaccine; 2006 Apr; 24(16):3290-7. PubMed ID: 16481076
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leishmania donovani p36(LACK) DNA vaccine is highly immunogenic but not protective against experimental visceral leishmaniasis.
    Melby PC; Yang J; Zhao W; Perez LE; Cheng J
    Infect Immun; 2001 Aug; 69(8):4719-25. PubMed ID: 11447143
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cysteine proteinase type I, encapsulated in solid lipid nanoparticles induces substantial protection against Leishmania major infection in C57BL/6 mice.
    Doroud D; Zahedifard F; Vatanara A; Najafabadi AR; Rafati S
    Parasite Immunol; 2011 Jun; 33(6):335-48. PubMed ID: 21410716
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Distinct immunological states in murine cutaneous leishmaniasis by immunising with different amounts of antigen: the generation of beneficial, potentially harmful, harmful and potentially extremely harmful states.
    Bretscher PA; Ogunremi O; Menon JN
    Behring Inst Mitt; 1997 Feb; (98):153-9. PubMed ID: 9382736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dendritic cells (DC) activated by CpG DNA ex vivo are potent inducers of host resistance to an intracellular pathogen that is independent of IL-12 derived from the immunizing DC.
    Ramírez-Pineda JR; Fröhlich A; Berberich C; Moll H
    J Immunol; 2004 May; 172(10):6281-9. PubMed ID: 15128817
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Conditions influencing the efficacy of vaccination with live organisms against Leishmania major infection.
    Tabbara KS; Peters NC; Afrin F; Mendez S; Bertholet S; Belkaid Y; Sacks DL
    Infect Immun; 2005 Aug; 73(8):4714-22. PubMed ID: 16040984
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Vaccination with the Leishmania infantum acidic ribosomal P0 protein plus CpG oligodeoxynucleotides induces protection against cutaneous leishmaniasis in C57BL/6 mice but does not prevent progressive disease in BALB/c mice.
    Iborra S; Carrión J; Anderson C; Alonso C; Sacks D; Soto M
    Infect Immun; 2005 Sep; 73(9):5842-52. PubMed ID: 16113303
    [TBL] [Abstract][Full Text] [Related]  

  • 14. DNA-Salmonella enterica serovar Typhimurium primer-booster vaccination biases towards T helper 1 responses and enhances protection against Leishmania major infection in mice.
    Lange UG; Mastroeni P; Blackwell JM; Stober CB
    Infect Immun; 2004 Aug; 72(8):4924-8. PubMed ID: 15271962
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oral immunization using live Lactococcus lactis co-expressing LACK and IL-12 protects BALB/c mice against Leishmania major infection.
    Hugentobler F; Di Roberto RB; Gillard J; Cousineau B
    Vaccine; 2012 Aug; 30(39):5726-32. PubMed ID: 22814408
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cellular vaccination with bone marrow-derived dendritic cells pulsed with a peptide of Leishmania infantum KMP-11 and CpG oligonucleotides induces protection in a murine model of visceral leishmaniasis.
    Agallou M; Margaroni M; Karagouni E
    Vaccine; 2011 Jul; 29(31):5053-64. PubMed ID: 21569815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leishmania major-infected murine langerhans cell-like dendritic cells from susceptible mice release IL-12 after infection and vaccinate against experimental cutaneous Leishmaniasis.
    von Stebut E; Belkaid Y; Nguyen BV; Cushing M; Sacks DL; Udey MC
    Eur J Immunol; 2000 Dec; 30(12):3498-506. PubMed ID: 11093169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dendritic cells in Leishmania infection.
    Brandonisio O; Spinelli R; Pepe M
    Microbes Infect; 2004 Dec; 6(15):1402-9. PubMed ID: 15596127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genetically resistant mice lacking interleukin-12 are susceptible to infection with Leishmania major and mount a polarized Th2 cell response.
    Mattner F; Magram J; Ferrante J; Launois P; Di Padova K; Behin R; Gately MK; Louis JA; Alber G
    Eur J Immunol; 1996 Jul; 26(7):1553-9. PubMed ID: 8766560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunization with the hybrid protein vaccine, consisting of Leishmania major cysteine proteinases Type I (CPB) and Type II (CPA), partially protects against leishmaniasis.
    Zadeh-Vakili A; Taheri T; Taslimi Y; Doustdari F; Salmanian AH; Rafati S
    Vaccine; 2004 May; 22(15-16):1930-40. PubMed ID: 15121305
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.